XPR – Lifestyle Demo
Author:
Knight Therapeutics
Knight Amends Normal Course Issuer Bid
March 23, 2026
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results
March 19, 2026
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
March 17, 2026
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
March 17, 2026
Notice of Knight Therapeutics’ Fourth Quarter and Year End 2025 Results Conference Call
March 12, 2026